IDEXX Historical Cash Flow
| IDXX Stock | USD 418.55 0.06 0.01% |
Analysis of IDEXX Laboratories cash flow over time is an excellent tool to project IDEXX Laboratories future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Begin Period Cash Flow of 129 M or Other Cashflows From Financing Activities of 64.7 M as it is a great indicator of IDEXX Laboratories ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining IDEXX Laboratories latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether IDEXX Laboratories is a good buy for the upcoming year.
IDEXX |
About IDEXX Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in IDEXX balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which IDEXX's non-liquid assets can be easily converted into cash.
IDEXX Laboratories Cash Flow Chart
Add Fundamental
Change In Working Capital
The difference in the amount of working capital from one period to the next, indicating the change in a company's short-term assets and liabilities.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Capital Expenditures
Capital Expenditures are funds used by IDEXX Laboratories to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of IDEXX Laboratories operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Net Income
Net income is one of the most important fundamental items in finance. It plays a large role in IDEXX Laboratories financial statement analysis. It represents the amount of money remaining after all of IDEXX Laboratories operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Most accounts from IDEXX Laboratories' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into IDEXX Laboratories current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in IDEXX Laboratories. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. For more information on how to buy IDEXX Stock please use our How to Invest in IDEXX Laboratories guide.At this time, IDEXX Laboratories' Stock Based Compensation is fairly stable compared to the past year. Net Borrowings is likely to rise to about 406.4 M in 2024, despite the fact that Change To Inventory is likely to grow to (27.2 M).
IDEXX Laboratories cash flow statement Correlations
Click cells to compare fundamentals
IDEXX Laboratories Account Relationship Matchups
High Positive Relationship
High Negative Relationship
IDEXX Laboratories cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | (37.3M) | (18.9M) | (52.9M) | (121.7M) | (28.7M) | (27.2M) | |
| Change In Cash | (33.5M) | 293.6M | (239.5M) | (31.9M) | 341.4M | 358.5M | |
| Free Cash Flow | 303.9M | 540.4M | 636.0M | 394.1M | 772.9M | 811.5M | |
| Change In Working Capital | (105.0M) | (31.8M) | (137.5M) | (273.5M) | (72.4M) | (68.8M) | |
| Begin Period Cash Flow | 123.8M | 90.3M | 383.9M | 144.5M | 112.5M | 129.0M | |
| Other Cashflows From Financing Activities | 133.6M | 24.0M | 25.9M | 18.3M | 33.9M | 64.7M | |
| Depreciation | 88.0M | 96.0M | 104.6M | 111.9M | 114.9M | 120.7M | |
| Other Non Cash Items | 2.9M | 8.8M | 9.3M | 10.8M | 7.6M | 7.9M | |
| Capital Expenditures | 155.2M | 107.6M | 119.5M | 148.8M | 133.6M | 140.3M | |
| Total Cash From Operating Activities | 459.2M | 648.1M | 755.5M | 543.0M | 906.5M | 951.8M | |
| Net Income | 427.8M | 582.1M | 744.8M | 679.1M | 845.0M | 887.3M | |
| Total Cash From Financing Activities | (286.4M) | (248.4M) | (697.4M) | (370.9M) | (442.0M) | (419.9M) | |
| End Period Cash Flow | 90.3M | 383.9M | 144.5M | 112.5M | 453.9M | 476.6M | |
| Sale Purchase Of Stock | (309.7M) | (182.8M) | (746.8M) | (819.7M) | (71.9M) | (75.5M) | |
| Total Cashflows From Investing Activities | (205.5M) | (109.4M) | (293.0M) | (195.4M) | (175.8M) | (167.0M) | |
| Change To Account Receivables | (22.5M) | (60.7M) | (33.1M) | (41.4M) | (53.9M) | (51.2M) | |
| Other Cashflows From Investing Activities | (50.6M) | (2.4M) | (173.4M) | (46.5M) | (41.9M) | (44.0M) | |
| Change To Liabilities | 2.0M | 981K | 11.2M | 3.5M | 3.1M | 3.0M | |
| Stock Based Compensation | 39.3M | 31.0M | 37.8M | 49.8M | 59.7M | 62.7M | |
| Investments | (205.5M) | (109.4M) | (293.0M) | (195.4M) | (144.0M) | (136.8M) | |
| Change Receivables | (22.5M) | (60.7M) | (33.1M) | (41.4M) | (37.3M) | (39.1M) | |
| Net Borrowings | (10.4M) | (94.7M) | 23.5M | 430.1M | 387.1M | 406.4M | |
| Cash And Cash Equivalents Changes | (32.8M) | 290.3M | (234.8M) | (23.3M) | (21.0M) | (19.9M) | |
| Cash Flows Other Operating | (47.1M) | 46.9M | (62.7M) | (113.9M) | (102.5M) | (97.4M) | |
| Change To Netincome | 48.3M | 1.7M | 148.2M | 25.5M | 29.4M | 28.4M | |
| Change To Operating Activities | (34.8M) | (31.8M) | (137.5M) | (102.8M) | (92.6M) | (87.9M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for IDEXX Stock Analysis
When running IDEXX Laboratories' price analysis, check to measure IDEXX Laboratories' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IDEXX Laboratories is operating at the current time. Most of IDEXX Laboratories' value examination focuses on studying past and present price action to predict the probability of IDEXX Laboratories' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IDEXX Laboratories' price. Additionally, you may evaluate how the addition of IDEXX Laboratories to your portfolios can decrease your overall portfolio volatility.